Inspire(US:INSP) Globenewswire·2025-11-14 18:50Core Viewpoint - Inspire Medical Systems, Inc. is facing a proposed class-action lawsuit for allegedly misleading investors regarding the commercial readiness and demand for its Inspire V sleep apnea device, leading to a significant stock decline [1][6]. Company Overview - Inspire Medical Systems, Inc. is under investigation by prominent investor rights law firm Hagens Berman for claims related to investor losses during the class period from August 6, 2024, to August 4, 2025 [2][3]. Allegations of Misleading Information - The lawsuit claims that Inspire assured investors it had met all regulatory and commercial prerequisites for the Inspire V launch while promoting high demand, which was later revealed to be untrue [3][4]. - The complaint highlights that the actual launch of Inspire V was disastrous, with minimal initial demand due to customers being stocked with older Inspire IV devices [4][5]. Impact of the Launch - On August 4, 2025, Inspire disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers [5][6]. - The company noted that although the CPT code for Inspire V was approved for Medicare patients, necessary software updates for claims processing were delayed until July 1, affecting billing and leading centers to continue using the older Inspire IV [5][6]. Financial Consequences - As a result of the poor launch performance, Inspire slashed its 2025 earnings guidance by 80%, projecting earnings of only $0.40 to $0.50 per share [6]. - Following this announcement, Inspire's stock price plummeted by approximately 32%, dropping $42.04 the next day [6].